Varex Imaging Stock Drops 13% Despite Revenue Increase in Q4; FY26 Forecast Weak
Stock Performance: Varex Imaging Corporation (VREX) saw a decline of 13.28% in its stock price, closing at $10.28 after releasing its fourth quarter and full-year 2025 financial results.
Revenue Growth: The company reported a fourth-quarter revenue increase of 11% year-over-year to $229 million, with significant growth in its Industrial segment and CT tube business, while full-year revenue reached $845 million, up about 4%.
Net Loss and Guidance: Despite revenue growth, Varex reported a net loss of $1.70 per share for FY25 and provided cautious guidance for FY26, anticipating first-quarter revenues between $200 million and $215 million and adjusted EPS of $0.05 to $0.25.
Market Reaction: The announcement led to unusually high trading volume as investors reacted to the mixed results and conservative outlook, with the stock's 52-week range noted at approximately $9.40 - $20.80.
Trade with 70% Backtested Accuracy
Analyst Views on VREX
About VREX
About the author

- Stable Revenue Performance: Varex Imaging reported Q2 revenue of $216 million, aligning with guidance, with a 2% increase in medical revenue driven by strong CT sales, indicating stability in both medical and industrial sectors despite some softness in industrial performance.
- Strong Gross Margin: The non-GAAP gross margin stood at 34%, at the high end of guidance, with non-GAAP EPS of $0.21, reflecting effective cost control amidst rising raw material prices, showcasing the company's resilience in maintaining profitability.
- Successful Debt Restructuring: The company completed debt refinancing, resulting in reduced outstanding debt and lower annual interest expenses, enhancing its capital structure and providing greater flexibility for future investments and growth initiatives.
- Optimistic Future Outlook: Full fiscal year 2026 revenue is expected to range between $860 million and $880 million, with Q3 revenue guidance set between $210 million and $225 million, demonstrating the company's confidence in future growth despite facing some cost and logistics challenges.
Q2 Adjusted EPS: VAREX Imaging reported an adjusted earnings per share (EPS) of USD 0.21 for the second quarter.
Comparison with Estimates: This EPS figure matches the estimates provided by IBES, which also projected an EPS of USD 0.21.
- Earnings Release Schedule: Varex Imaging Corporation will announce its unaudited financial results for Q2 of fiscal year 2026 after market close on May 7, 2026, which is expected to significantly impact investor sentiment.
- Conference Call Details: Following the earnings release, Varex will host a conference call at 3:00 PM Mountain Time, allowing investors to participate via 877-524-8416 (U.S.) or 412-902-1028 (non-U.S.), enhancing investor engagement and communication.
- Webcast and Replay Availability: The conference call will be webcast live and accessible on the company's website, with a replay available from May 7 to May 21, ensuring broad dissemination of information and transparency for stakeholders.
- Company Background: Varex Imaging Corporation is a leading manufacturer of X-ray imaging components with over 70 years of innovation, whose products are utilized in medical, industrial, and security imaging applications, underscoring its significant market presence.
- Credit Agreement Overview: Varex Imaging has entered into a $490 million Credit and Guaranty Agreement on March 13, 2026, which includes a $350 million secured term loan and a $100 million secured revolving credit facility, maturing in 2031, thereby enhancing the company's financial flexibility.
- Debt Redemption Plan: The company plans to redeem $368 million of its 7.875% Senior Secured Notes on March 16, 2026, using funds from the new credit agreement, which is expected to reduce annual cash interest expenses by over $7 million, significantly improving its financial position.
- Interest Rate Management Strategy: Varex has entered into an interest rate swap that effectively fixes the variable SOFR rate at 3.65%, with an applicable margin set at 2.50%, which will help lower financing costs and enhance future free cash flow generation capabilities.
- Strategic Investment Direction: The CFO stated that this financing will support continued investment in the core business while prioritizing long-term shareholder value, demonstrating the company's confidence and commitment to future growth.
- Investor Conference Schedule: Varex Imaging announced its participation in Oppenheimer's 36th Annual Healthcare, MedTech & Services Virtual Conference on March 17, 2025, at 10:40 AM ET, and the Sidoti Small Cap Virtual Conference on March 18, 2026, at 1:00 PM ET, showcasing the company's innovations and market outlook in medical imaging.
- Webcast Access: Investors can access the conferences via the company's website or provided webcast links, ensuring transparent communication with investors and enhancing market confidence.
- Company Background: Varex Imaging is a leading innovator in X-ray imaging components with over 70 years of successful innovation history, with products widely used in medical, industrial, and security imaging, demonstrating the company's deep technological expertise.
- Global Workforce Distribution: Varex employs approximately 2,400 people across North America, Europe, and Asia, showcasing its global operational capabilities and market reach, further solidifying its leadership position in the imaging industry.









